Surveillance of cfDNA Hot Spot Mutations in NSCLC Patients during Disease Progression
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24086958 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Agne Sestokaite und 4 weiteren Autor:innen. Beteiligte Einrichtung: National Cancer Institute, Santariskiu 1, 08406 Vilnius, Lithuania. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This research was funded by by National Cancer Institute Research Fund (Santariskiu 1, Vilnius 08406, Lithuania), National Cancer Institute Research Fund.
Abstract (Originalsprache)
Non-small cell cancer (NSCLC) has been identified with a great variation of mutations that can be surveyed during disease progression. The aim of the study was to identify and monitor lung cancer-specific mutations incidence in cell-free DNA as well as overall plasma cell-free DNA load by means of targeted next-generation sequencing. Sequencing libraries were prepared from cell-free DNA (cfDNA) isolated from 72 plasma samples of 41 patients using the Oncomine Lung cfDNA panel covering hot spot regions of 11 genes. Sequencing was performed with the Ion Torrent™ Ion S5™ system. Four genes were detected with highest mutation incidence: KRAS (43.9% of all cases), followed by ALK (36.6%), TP53 (31.7%), and PIK3CA (29.3%). Seven patients had co-occurring KRAS + TP53 (6/41, 14.6%) or KRAS + PIK3CA (7/41, 17.1%) mutations. Moreover, the mutational status of TP53 as well an overall cell-free DNA load were confirmed to be predictors of poor progression-free survival (HR = 2.5 [0.8–7.7]; p = 0.029 and HR = 2.3 [0.9–5.5]; p = 0.029, respectively) in NSCLC patients. In addition, TP53 mutation status significantly predicts shorter overall survival (HR = 3.4 [1.2–9.7]; p < 0.001). We demonstrated that TP53 mutation incidence as well as a cell-free DNA load can be used as biomarkers for NSCLC monitoring and can help to detect the disease progression prior to radiological confirmation of the status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Cancer Institute, Santariskiu 1, 08406 Vilnius, Lithuania.
- Institute of Biosciences, Life Sciences Center, Vilnius University, Sauletekio Ave. 7, 10257 Vilnius, Lithuania.
ORCID-Profile: Agne Sestokaite, Rasa Sabaliauskaite
Förderung
- This research was funded by by National Cancer Institute Research Fund (Santariskiu 1, Vilnius 08406, Lithuania)
- National Cancer Institute Research Fund
Zitieren
APA
Sestokaite, A., Gedvilaite, V., Cicenas, S., Sabaliauskaite, R., & Jarmalaite, S. (2023). Surveillance of cfDNA Hot Spot Mutations in NSCLC Patients during Disease Progression. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24086958
Vancouver
Sestokaite A, Gedvilaite V, Cicenas S, Sabaliauskaite R, Jarmalaite S. Surveillance of cfDNA Hot Spot Mutations in NSCLC Patients during Disease Progression. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24086958
BibTeX
@article{Sestokaite2023,
author = {Sestokaite, Agne and Gedvilaite, Vaida and Cicenas, Saulius and Sabaliauskaite, Rasa and Jarmalaite, Sonata},
title = {Surveillance of cfDNA Hot Spot Mutations in NSCLC Patients during Disease Progression},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24086958}
}
EUVIMED